Kathryn E. Hitchcock

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Steven J. Hughes · 5 shared papers, 2017–2026 · strength 0.88
   • Paper Neoadjuvant Therapy for Localized Pancreatic Cancer. DOI 10.3390/cancers18061011↗
   • Paper Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI… DOI 10.1093/oncolo/oyag250↗
   • Paper National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. DOI 10.1016/j.hpb.2023.06.018↗
2. Ibrahim Nassour · 4 shared papers, 2023–2026 · strength 0.82
   • Paper Neoadjuvant Therapy for Localized Pancreatic Cancer. DOI 10.3390/cancers18061011↗
   • Paper Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI… DOI 10.1093/oncolo/oyag250↗
   • Paper National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. DOI 10.1016/j.hpb.2023.06.018↗
3. Jesus C. Fabregas · 4 shared papers, 2023–2026 · strength 0.82
   • Paper Neoadjuvant Therapy for Localized Pancreatic Cancer. DOI 10.3390/cancers18061011↗
   • Paper Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI… DOI 10.1093/oncolo/oyag250↗
   • Paper National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. DOI 10.1016/j.hpb.2023.06.018↗
4. Thomas J. George · 4 shared papers, 2023–2026 · strength 0.82
   • Paper Neoadjuvant Therapy for Localized Pancreatic Cancer. DOI 10.3390/cancers18061011↗
   • Paper Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI… DOI 10.1093/oncolo/oyag250↗
   • Paper National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. DOI 10.1016/j.hpb.2023.06.018↗
5. Sherise Chantell Rogers · 3 shared papers, 2023–2026 · strength 0.56
   • Paper Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI… DOI 10.1093/oncolo/oyag250↗
   • Paper National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. DOI 10.1016/j.hpb.2023.06.018↗
   • Paper A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. DOI 10.2217/fon-2023-0256↗
6. Alessandro Paniccia · 2 shared papers, 2023–2026 · strength 0.43
   • Paper Neoadjuvant Therapy for Localized Pancreatic Cancer. DOI 10.3390/cancers18061011↗
   • Paper National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. DOI 10.1016/j.hpb.2023.06.018↗
7. Ryan Michael Thomas · 2 shared papers, 2023–2026 · strength 0.39
   • Paper Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI… DOI 10.1093/oncolo/oyag250↗
   • Paper A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. DOI 10.2217/fon-2023-0256↗
8. Omar Roger Kayaleh · 2 shared papers, 2023–2026 · strength 0.39
   • Paper Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI… DOI 10.1093/oncolo/oyag250↗
   • Paper A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. DOI 10.2217/fon-2023-0256↗
9. Aleksey A. Novikov · 1 shared paper, 2026 · strength 0.26
   • Paper Neoadjuvant Therapy for Localized Pancreatic Cancer. DOI 10.3390/cancers18061011↗
10. Abdul Qahar Khan Yasinzai · 1 shared paper, 2026 · strength 0.26
    • Paper Neoadjuvant Therapy for Localized Pancreatic Cancer. DOI 10.3390/cancers18061011↗
11. Patrick W. Underwood · 1 shared paper, 2026 · strength 0.26
    • Paper Neoadjuvant Therapy for Localized Pancreatic Cancer. DOI 10.3390/cancers18061011↗
12. Jordan A. McKean · 1 shared paper, 2026 · strength 0.26
    • Paper Neoadjuvant Therapy for Localized Pancreatic Cancer. DOI 10.3390/cancers18061011↗
13. Bashar J. Qumseya · 1 shared paper, 2026 · strength 0.26
    • Paper Neoadjuvant Therapy for Localized Pancreatic Cancer. DOI 10.3390/cancers18061011↗
14. Z. Hugh Fan · 1 shared paper, 2026 · strength 0.24
    • Paper Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI… DOI 10.1093/oncolo/oyag250↗
15. Ruchi Singhal · 1 shared paper, 2023 · strength 0.15
    • Paper A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. DOI 10.2217/fon-2023-0256↗
16. John Andrew Stauffer · 1 shared paper, 2017 · strength 0.06
    • Paper Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer. DOI 10.4240/wjgs.v9.i4.103↗
17. Romaine Charles Nichols · 1 shared paper, 2017 · strength 0.06
    • Paper Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer. DOI 10.4240/wjgs.v9.i4.103↗
18. Michael S. Rutenberg · 1 shared paper, 2017 · strength 0.06
    • Paper Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer. DOI 10.4240/wjgs.v9.i4.103↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.